11th October 2023 6:00PM BST - Virtual
BRUKINSA®▼ (zanubrutinib): A BTK inhibitor with a difference – Shaping the future of CLL treatment in Scotland
This live virtual meeting brought together expert clinicians to discuss BRUKINSA, a next-generation BTK inhibitor, as a treatment option for patients with CLL.
Topics included clinical evidence supporting the use of BRUKINSA, patient case studies, the use of BRUKINSA in the NHS, and concluded with a panel-led Q&A session.
On-demand video content from this meeting will be available soon.
Agenda
Speakers
Dr Mark Rafferty
Consultant Haematologist, Beatson West of Scotland Cancer Centre
Dr Rafferty is a Consultant in Clinical Experimental Haematology at the Beatson West of Scotland Cancer Centre and an Honorary Clinical Senior Lecturer at the University of Glasgow School of Medicine. He has a specialist interest in clinical trials in haemato-oncology and acts as Principal Investigator or Co-Investigator across a number of clinical trials in CLL at the Beatson centre. He is also active in the Beatson regional flow cytometry diagnostic service.
Dr Renata Walewska
Consultant Haematologist, UH Dorset NHS Foundation Trust, Chair, UK CLL, England
Dr Walewska has been a Consultant Haematologist at the Royal Bournemouth Hospital since 2010. Since March 2019 she has chaired the UK CLL Forum. In addition, she is part of the writing committee that updated the national BSH CLL guidelines and is an invited clinical advisor to the Evidence Review Group for NICE appraisals.
Dr Talha Munir
Consultant Haematologist, Leeds Teaching Hospitals NHS Trust, England
Dr Munir has worked in the Leeds NHS trust since 2014 as Consultant Haematologist. His main clinical and research interests are in CLL and paroxysmal nocturnal haemoglobinuria (PNH). He is one of the PNH consultants working in the PNH National Service, a sub-investigator for the NCRI CLL clinical trials and he is involved in multiple studies at Leeds Teaching Hospital.